THERACRYF PLC (TCF) — Investor Presentation

Investor webinar replay

Replay transcript excerpt

Good morning, and welcome to the THERACRYF PLC Investor Presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged and they can be submitted at any time using the Q and A tab situated on the right hand corner of your screen. Just simply type in your questions and press send. Before we begin, I would like to submit the following poll. And I would now like to hand you over to CEO, Hugh Jones. Good morning to you, sir. Good morning, Alex. Good morning, everybody. Thanks for attending. I'm Hugh. We've we've probably met before on these screens, and with me is doctor Helen Kuhlman, our chief operating officer. We're gonna dwell today particularly on two RNS releases made in the last couple of weeks, really about, what the significance of the IP we've filed is and indeed the significance of, through our, smoothed out manufacturing process, the two kilograms of clinical grade material we've just manufactured readiness for eventual clinical trials. But I'm gonna start with just orientating everybody to THERACRYF. We are we have pivoted to a neuropsychiatry company, and what we do now predominantly is developing innovative therapeutics in specific neuropsychiatric disorders. Because we're public, the usual disclaimers apply. And here's the one page summary as ever. We're aim listed tcf.l. We're a classical biotech following a classical biotech business model. The key areas within neuropsychiatry that we focus on are addiction with our orexin one blocker or orexin one antagonist, which is a novel agent and, best in class, we believe, suitable for addictions or impulsive addictions to food, alcohol, and certain drugs. And that program is funded to all the data being ready for clinic readiness by quarter three of this yea...